X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Kartos is collaborating with Tempus to use the xT assay, a 648-gene panel, to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may benefit from treatment with KRT-232 (navtemadlin, a small molecule MDM2 inhibitor).
Lead Product(s): Navtemadlin
Therapeutic Area: Oncology Product Name: KRT-232
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kartos Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 06, 2022
Details:
The initial focus of the collaboration will be the co-development of multiple CDx claims in blood cancers for Kartos’ KRT-232, a potent and selective oral MDM2 inhibitor that activates p53 to drive tumor cell death in TP53 wild-type cancers.
Lead Product(s): Navtemadlin
Therapeutic Area: Oncology Product Name: KRT-232
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Illumina
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 24, 2021
Details:
El-Deiry hopes that blocking MDM2, either through gene-silencing or the MDM2-inhibiting drug AMG-232, could be especially helpful for people with hyperprogression.
Lead Product(s): Navtemadlin
Therapeutic Area: Oncology Product Name: AMG-232
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
